{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 110,
  "pageCount": 197,
  "prevPage": 109,
  "nextPage": 111,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses a screenshot of a research report with a callout box to emphasize the contradiction.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bullet_list",
    "screenshot",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/110",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-110",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.42,
        "x": 0.54,
        "y": 0.4
      },
      "kind": "callout",
      "text": "Bristol-Myers management was \"aware that this class patent could be a roadblock to ozanimod commercialization,\" yet has continued to promote the product's blockbuster potential to shareholders, even going as far as to call ozanimod \"de-risked\"",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cecb6d45-1d2d-4a5d-85be-14fcbe0874fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "Bristol-Myers management was “aware that this class patent could be a roadblock to ozanimod commercialization,” yet has continued to promote the product’s blockbuster potential to shareholders, even going as far as to call ozanimod “de-risked”.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d3-706e-a453-a134d4e589c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.48,
        "x": 0.04,
        "y": 0.32
      },
      "kind": "image",
      "text": "Excerpt From Credit Suisse Research Report (March 2019)",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dffa248e-32dd-4401-8523-834297d62504",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "We believe a Credit-Suisse report published this month is the first time that Bristol-Myers shareholders have been made aware of a potential IP issue with ozanimod.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e2a29e6-055e-41b2-88d8-907f832b744e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Bristol-Myers shareholders only recently learned that Novartis may potentially have blocking IP on ozanimod.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e4effc6-0dd7-4eb8-bff0-38a18f108043",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "Did Bristol-Myers miss the IP issues with ozanimod during their two weeks of full data room access? Why did management not disclose this risk to shareholders given the significance of ozanimod to Celene's pipeline?",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ff8fed4-7db1-4696-9b78-9ea95fad4330",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“Bristol-Myers management was “aware that this class patent could be a roadblock to ozanimod commercialization,” yet has continued to promote the product’s blockbuster potential to shareholders, even going as far as to call ozanimod “de-risked”” — Starboard Value",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d3-706e-a453-a4b194a39d11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.04,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: Public company transcripts, Wall Street research.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3bfe06a-bd5d-454d-9678-2507b7b440d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "In Addition, Ozanimod May Have a Serious Intellectual Property (\"IP\") Issue",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1810117-c3fe-4cdd-8e3f-caac0b51e7ec",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "ceo-quote-contradiction",
      "slug": null,
      "matchId": "ddf481c4-520e-4408-afe4-3d43486f959a",
      "evidence": "Contrasts management's public 'de-risked' claim with internal awareness of patent roadblock.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}